Den vigtigste målestok for virkningen i undersøgelsen af hepatocellulært karcinom var patientens samlede overlevelsestid.
In the study of hepatocellular carcinoma, the patients taking Nexavar survived for an average of 10.7 months, compared with 7.9 months in those taking placebo.